Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.
Saved in:
| Title: | Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. |
|---|---|
| Authors: | Ruan DY; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Lin SY; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Huang JJ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Li YH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Li N; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Qu XJ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China., Du XB; Departmant of Oncology, Nuclear Medicine Laboratory of Mianyang Central Hospital, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China., Yin YM; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Yuan ZY; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Shi YX; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Xu F; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., An X; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Hong RX; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Xia W; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Xue C; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Bi XW; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Jiang KK; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Zheng QF; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Zhang YQ; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Peng JJ; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Liu ZY; Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, China., Xiong HH; Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Suo AL; Departmant of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China., Lin RB; Department of Gastrointestinal Oncology, Fujian Cancer Hospital, Fuzhou, China., Zhang S; Department of Biological Treatment, West China Hospital, Sichuan University, Chengdu, China., Tang SN; Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Yu Y; Department of Clinical Biostatistics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Li X; Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Wang X; Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Tian X; Preclinical Development Department, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Lv P; Preclinical Development Department, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Shen C; Preclinical Development Department, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Lou LG; Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Wang L; Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Zhang ZP; Innovative Biopharmaceutical Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Xu TJ; Innovative Biopharmaceutical Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Chen TX; Innovative Biopharmaceutical Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Wang SS; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. Electronic address: wangshs@sysucc.org.cn., Xu RH; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. Electronic address: xurh@sysucc.org.cn. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 May 15. Date of Electronic Publication: 2026 May 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
